Eam Investors, LLC Ideaya Biosciences, Inc. Transaction History

Eam Investors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$34.2 - $47.13 $842,209 - $1.16 Million	-24,626 Reduced 22.78%	83,484 $3.66 Million
Q4 2023 Feb 13, 2024	BUY	$24.59 - $35.83 $502,816 - $732,651	20,448 Added 23.33%	108,110 $3.85 Million
Q3 2023 Nov 13, 2023	BUY	$21.07 - $29.77 $1.1 Million - $1.56 Million	52,299 Added 147.89%	87,662 $2.37 Million
Q2 2023 Aug 11, 2023	BUY	$13.33 - $25.53 $471,388 - $902,817	35,363 New	35,363 $831,000
Q3 2021 Nov 12, 2021	SELL	$17.26 - $27.08 $842,460 - $1.32 Million	-48,810 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$17.76 - $24.83 $297,675 - $416,175	-16,761 Reduced 25.56%	48,810 $1.03 Million
Q1 2021 May 11, 2021	BUY	$13.48 - $23.77 $883,897 - $1.56 Million	65,571 New	65,571 $1.54 Million
Q4 2020 Feb 11, 2021	SELL	$12.17 - $17.52 $1.43 Million - $2.06 Million	-117,842 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$11.22 - $14.46 $57,738 - $74,411	-5,146 Reduced 4.18%	117,842 $1.48 Million
Q2 2020 Aug 13, 2020	BUY	$3.59 - $18.57 $441,526 - $2.28 Million	122,988 New	122,988 $1.75 Million

217

81.2M

69K

20K

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.08B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.